GRIT Biotechnology
Blood & Organ Banks · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1-5 building 24 Lane 388 Shengrong Flori...Website
www.grit-bio.comRevenue
$20.9 MillionIndustry
ZI Rank: 3
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
2
2
3
2
3
About GRIT Biotechnology
Founded in 2019, based out of Shanghai, China, GRIT Biotechnology is a biotherapeutics company with a focus on Tumor Infiltrating Lymphocytes (TIL) therapies.Explore more
GRIT Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GRIT Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
GRIT Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when GRIT Biotechnology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if GRIT Biotechnology is spiking on competitors!
Click to see if GRIT Biotechnology had a recent Job posting/layoffs
Earning: See what the market has to say on GRIT Biotechnology recently announced quarterly report
Check if GRIT Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once GRIT Biotechnology has new funding data
Congratulate Masked Content for being promoted to Masked Content at GRIT Biotechnology
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
GRIT Biotechnology is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
GRIT Biotechnology is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about GRIT Biotechnology.
GRIT Biotechnology financials insights
Gather financial insights about GRIT Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$60M
GRIT Biotechnology Tech Stack
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
GRIT Biotechnology News & Media
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based...Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio"), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6–9, 2025, in Orlando, Florida, USA. The abstract, titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNAGrit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting
SHANGHAI, May 29, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL) therapies will be presented at the American Society of Clinical Oncology (ASCO) 42nd annual meeting, which is taking place in Chicago, IL from May 30th to June 3rd. Grit Bio will provide the clinical updates of its leading TIL programs, including GT101Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting
SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ("Vitalgen"), will be showcased in one oral presentation and two poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 28th annual meeting in New Orleans, LA from May 13th to 17th. Grit Bio will provide the updates of three preclinical programs
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GRIT Biotechnology
Sign Up For FreeTo access detailed company insights
Founded in 2019, based out of Shanghai, China, GRIT Biotechnology is a biotherapeutics company with a focus on Tumor Infiltrating Lymphocytes (TIL) therapies.... Read More
